End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
Apr. 10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 22-09-26 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 22-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Wayne Linsley
BRD | Director/Board Member | 67 | 20-01-15 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 20-09-30 |
Jeff Pavell
BRD | Director/Board Member | 57 | 22-09-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,096,489 | 2,663,202 ( 86.01 %) | 252,855 ( 8.166 %) | 86.01 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-4.64% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- SILO Stock
- GDSW Stock
- Company GOLD SWAP